newsfilter
← Latest News
GlobeNewswire·

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

  • Ascentage Pharma presented four-year follow-up data for Olverembatinib at the 67th ASH Annual Meeting showing a median event-free survival of 21.2 months versus 2.9 months for the best available therapy (BAT) arm.
  • The study demonstrated significant efficacy for patients without the T315I mutation, with a median event-free survival of 11.9 months for Olverembatinib compared to 3.1 months for BAT.
  • Olverembatinib exhibited a favorable safety profile with a 7% vascular occlusion rate and no new safety signals observed during the four-year follow-up.
  • The drug showed superior complete hematologic response rates (85% vs 35%), complete cytogenetic response rates (38% vs 19%), and major molecular response rates (30% vs 8%) compared to BAT in the overall CML-CP population.
  • Olverembatinib is a third-generation BCR-ABL1 inhibitor approved in China for TKI-resistant/intolerant CML-CP and CML-AP, including cases with T315I mutations, with all indications covered by the China National Reimbursement Drug List.
  • Ascentage Pharma is conducting three global Phase III registrational studies for Olverembatinib in CML-CP, newly diagnosed Ph+ ALL, and SDH-deficient GIST.
  • An exclusive option agreement exists for Takeda to license global rights for Olverembatinib outside of mainland China, Hong Kong, Macau, and Taiwan.
  • The registrational Phase II trial (NCT04126681) enrolled 144 patients randomized 2:1 to Olverembatinib or investigator's choice of BAT.